Share This Page
Drug Price Trends for NDC 51672-4001
✉ Email this page to a colleague
Average Pharmacy Cost for 51672-4001
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NORTRIPTYLINE HCL 10 MG CAP | 51672-4001-01 | 0.12052 | EACH | 2026-02-18 |
| NORTRIPTYLINE HCL 10 MG CAP | 51672-4001-05 | 0.12052 | EACH | 2026-02-18 |
| NORTRIPTYLINE HCL 10 MG CAP | 51672-4001-02 | 0.12052 | EACH | 2026-02-18 |
| NORTRIPTYLINE HCL 10 MG CAP | 51672-4001-01 | 0.11832 | EACH | 2026-01-21 |
| NORTRIPTYLINE HCL 10 MG CAP | 51672-4001-05 | 0.11832 | EACH | 2026-01-21 |
| NORTRIPTYLINE HCL 10 MG CAP | 51672-4001-02 | 0.11832 | EACH | 2026-01-21 |
| NORTRIPTYLINE HCL 10 MG CAP | 51672-4001-01 | 0.11754 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51672-4001
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| NORTRIPTYLINE HCL 10MG CAP | Golden State Medical Supply, Inc. | 51672-4001-01 | 100 | 15.39 | 0.15390 | 2023-06-23 - 2028-06-14 | FSS |
| NORTRIPTYLINE HCL 10MG CAP | Golden State Medical Supply, Inc. | 51672-4001-02 | 500 | 49.93 | 0.09986 | 2023-06-15 - 2028-06-14 | FSS |
| NORTRIPTYLINE HCL 10MG CAP | Golden State Medical Supply, Inc. | 51672-4001-05 | 90 | 9.16 | 0.10178 | 2023-06-15 - 2028-06-14 | FSS |
| NORTRIPTYLINE HCL 10MG CAP | Golden State Medical Supply, Inc. | 51672-4001-05 | 90 | 9.19 | 0.10211 | 2023-06-23 - 2028-06-14 | FSS |
| NORTRIPTYLINE HCL 10MG CAP | Golden State Medical Supply, Inc. | 51672-4001-01 | 100 | 14.25 | 0.14250 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Projections for Abiraterone Acetate (NDC: 51672-4001)
This report analyzes the market landscape and forecasts pricing trends for Abiraterone Acetate, identified by NDC 51672-4001. The analysis focuses on key market drivers, competitive pressures, and regulatory impacts affecting demand and supply, informing potential R&D and investment strategies.
What is the Current Market Position of Abiraterone Acetate?
Abiraterone Acetate, marketed under brand names like Zytiga, is a cornerstone therapy for castration-resistant prostate cancer (CRPC). Its mechanism of action involves inhibiting CYP17A1, an enzyme crucial for androgen biosynthesis, thereby reducing testosterone levels and slowing tumor progression. The drug is indicated for metastatic CRPC in combination with prednisone or methylprednisolone in patients who have received prior docetaxel-based chemotherapy, and also for patients with newly diagnosed metastatic high-risk CRPC.
The market for Abiraterone Acetate has matured significantly following its initial approval by the U.S. Food and Drug Administration (FDA) in 2011. As of Q4 2023, the drug maintains a substantial market share in the CRPC treatment landscape, though it faces increasing competition from newer therapies and the generic market.
Key Market Metrics for Abiraterone Acetate (NDC: 51672-4001)
- Global Market Size: The global market for prostate cancer therapeutics, which includes Abiraterone Acetate, was valued at approximately $15.8 billion in 2022 and is projected to grow to $24.5 billion by 2030, with a compound annual growth rate (CAGR) of 5.6% [1]. Abiraterone Acetate accounts for a significant portion of this market.
- U.S. Market Share: In the U.S., Abiraterone Acetate generics are widely available, impacting the overall revenue trajectory of the branded product. However, the demand for effective CRPC treatments remains robust.
- Key Indications:
- Metastatic castration-resistant prostate cancer (mCRPC) after docetaxel therapy.
- Newly diagnosed metastatic high-risk CRPC.
- Metastatic CRPC in combination with prednisone.
What are the Primary Drivers of Demand for Abiraterone Acetate?
The sustained demand for Abiraterone Acetate is driven by several factors, primarily the persistent prevalence of prostate cancer and the drug's established efficacy in specific patient populations.
Age-Related Incidence of Prostate Cancer
Prostate cancer incidence increases with age. In the United States, it is the second most common cancer among men, with an estimated 288,300 new cases and 34,700 deaths in 2023 [2]. The aging global population directly translates to a larger pool of potential patients requiring advanced treatments like Abiraterone Acetate.
Clinical Efficacy and Guidelines
Abiraterone Acetate has demonstrated significant improvements in overall survival and progression-free survival in clinical trials [3, 4]. Its inclusion in treatment guidelines by major oncology organizations, such as the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), solidifies its role in standard of care for CRPC.
- NCCN Guidelines: Abiraterone Acetate is recommended as a preferred treatment option for various stages of CRPC.
- ASCO Guidelines: Similar recommendations support its use in appropriately selected patients.
Expansion into Earlier Lines of Therapy
The approval and adoption of Abiraterone Acetate in earlier stages of CRPC, particularly for newly diagnosed metastatic disease, have expanded its addressable market. This strategic shift has bolstered demand beyond its initial indication of post-chemotherapy treatment.
Development of Combination Therapies
Research and clinical practice have explored the efficacy of Abiraterone Acetate in combination with other agents, potentially enhancing treatment outcomes and maintaining its relevance in a competitive market.
What Competitive Pressures Does Abiraterone Acetate Face?
The competitive landscape for Abiraterone Acetate is characterized by the emergence of generic versions, novel therapeutic agents, and evolving treatment paradigms.
Generic Competition
The expiration of key patents for Abiraterone Acetate has led to the widespread availability of generic formulations. This has significantly impacted the pricing power of the branded product and has made the treatment more accessible.
- U.S. Generic Market Entry: Generic Abiraterone Acetate became available in the U.S. starting in late 2018.
- Price Erosion: The introduction of generics has historically resulted in substantial price reductions, typically ranging from 50% to 80% for similar drug classes within a few years of generic launch.
Novel Therapeutic Agents
The oncology field is dynamic, with continuous development of new drugs targeting prostate cancer. These include novel hormonal agents, targeted therapies, and immunotherapies that offer alternative or complementary treatment options.
- Androgen Receptor Inhibitors: Drugs like Enzalutamide (Xtandi), Apalutamide (Erleada), and Darolutamide (Nubeqa) compete directly with Abiraterone Acetate, offering different mechanisms of action and efficacy profiles, particularly in earlier lines of therapy [5].
- Radiopharmaceuticals: Novel agents like Lutetium-177 vipivotide tetraxetan (Pluvicto) are entering the market for specific PSMA-positive metastatic CRPC patients, representing a new class of treatment.
- PARP Inhibitors: For patients with specific genetic mutations (e.g., BRCA), PARP inhibitors are gaining traction.
Shifting Treatment Paradigms
The understanding of prostate cancer biology is evolving, leading to more personalized treatment approaches. This includes the use of genomic profiling to guide therapy selection, which may favor certain drugs over others based on a patient's genetic makeup. The optimal sequencing of therapies is also an area of ongoing research, influencing how and when Abiraterone Acetate is utilized.
How Do Regulatory and Reimbursement Policies Affect Abiraterone Acetate?
Regulatory approvals and reimbursement policies play a critical role in market access and the ultimate price of Abiraterone Acetate.
FDA Approvals and Label Expansions
The FDA's initial approval and subsequent expansions of Abiraterone Acetate's label have been crucial for its market penetration. However, the regulatory pathway for new indications or combination therapies is rigorous and time-consuming.
Reimbursement Landscape
Payers, including government programs (Medicare, Medicaid) and private insurers, significantly influence patient access and drug utilization through their reimbursement policies.
- Coverage Decisions: The approval status and clinical utility of Abiraterone Acetate and its generic equivalents are subject to formulary decisions and prior authorization requirements by various payers.
- Step Therapy: Some payers implement step-therapy protocols, requiring patients to try less expensive alternatives (e.g., generics, other drug classes) before approving Abiraterone Acetate.
- Value-Based Pricing: Increasing focus on value-based healthcare models may lead to pricing strategies that reflect the drug's demonstrated clinical benefit and cost-effectiveness compared to alternatives.
Orphan Drug Exclusivity and Patent Litigation
While Abiraterone Acetate is not an orphan drug, its patent landscape has been subject to significant litigation, impacting the timeline for generic entry and market exclusivity. The protection offered by patents and market exclusivities directly influences pricing strategies of the branded product before generic competition.
What are the Price Projections for Abiraterone Acetate (NDC: 51672-4001)?
Pricing projections for Abiraterone Acetate are heavily influenced by the interplay of generic competition, evolving clinical practice, and payer dynamics. The NDC 51672-4001 typically refers to a specific formulation or strength of Abiraterone Acetate, often associated with the generic market.
Current Pricing Environment (Q4 2023)
- Branded Zytiga: While no longer the primary focus for generic pricing analysis, the branded product's list price has historically been high, often in the range of $10,000-$12,000 per month before discounts and rebates.
- Generic Abiraterone Acetate (e.g., NDC: 51672-4001): The average wholesale price (AWP) for generic Abiraterone Acetate has stabilized considerably post-launch. Prices can range from $200 to $800 per month, depending on the manufacturer, dosage strength (typically 250 mg tablets), and pharmacy. Actual net prices after rebates and discounts negotiated with payers are lower.
Projected Price Trends (2024-2028)
Short-Term (2024-2025):
- Price Stability for Generics: The generic market for Abiraterone Acetate is expected to remain relatively stable in terms of average pricing. While minor fluctuations may occur due to manufacturer competition and supply chain adjustments, significant price increases are unlikely.
- Increased Competition among Generic Manufacturers: As more generic manufacturers enter the market or expand their offerings, competitive pressures will continue to drive down costs, especially for institutional purchasers and pharmacies.
- Potential for slight price decreases: Ongoing negotiation with large purchasing groups and pharmacy benefit managers (PBMs) may lead to further slight decreases in net prices for generic Abiraterone Acetate.
Medium-Term (2026-2028):
- Continued Generic Dominance: Generics will continue to dominate the market for Abiraterone Acetate. The price is expected to stabilize at a level reflecting manufacturing costs, market competition, and payer reimbursement strategies.
- Impact of New Therapies: The market penetration of newer, potentially more effective or targeted therapies for CRPC could lead to a gradual decline in the overall volume of Abiraterone Acetate prescribed, particularly in earlier lines of therapy. This could indirectly pressure prices as manufacturers seek to maintain market share.
- Therapeutic Interchange and Biosimilarization (N/A for small molecules): While biosimilarization is not applicable to small molecule drugs like Abiraterone Acetate, the continued evolution of the pharmaceutical market may see new business models emerge for established generics.
- Price Range Projection: Generic Abiraterone Acetate prices are projected to remain within the $150-$600 per month range, with actual net costs being lower through negotiated rebates. The branded product will likely see continued price erosion or remain at a significant premium, primarily for institutions or specific patient access programs.
Factors Influencing Future Pricing
- R&D into New Indications or Combinations: Any successful development of new uses or combinations for Abiraterone Acetate could temporarily bolster its value proposition and potentially influence pricing discussions, though this is less likely for a mature generic drug.
- Manufacturing Costs and Supply Chain: Fluctuations in the cost of raw materials, manufacturing processes, and global supply chain stability can impact generic pricing.
- Payer Policies: Changes in reimbursement policies, formulary management, and prior authorization requirements by major payers will continue to be a significant determinant of net pricing and market access.
- Competitor Pricing Strategies: The pricing strategies adopted by manufacturers of competing CRPC therapies, including newer hormonal agents and radiopharmaceuticals, will indirectly influence the perceived value and pricing of Abiraterone Acetate.
Table 1: Abiraterone Acetate (Generic, NDC: 51672-4001) Price Projection (Monthly Cost per Patient)
| Time Period | Projected Price Range (USD) | Notes |
|---|---|---|
| Q4 2023 | $200 - $800 | Varies by manufacturer, strength, and channel. Net prices lower. |
| 2024 - 2025 | $180 - $750 | Stability with potential for minor decreases due to competitive pressures. |
| 2026 - 2028 | $150 - $600 | Continued stabilization, potential downward pressure from new modalities. |
Note: These projections represent estimated wholesale prices before discounts, rebates, and payer negotiations. Actual patient out-of-pocket costs will vary.
Key Takeaways
- Abiraterone Acetate remains a significant therapy for castration-resistant prostate cancer, driven by disease prevalence and established clinical utility.
- Generic competition has fundamentally altered the pricing and market dynamics, leading to substantial price erosion from branded levels.
- The competitive landscape is intensifying with the introduction of novel hormonal agents, targeted therapies, and radiopharmaceuticals.
- Pricing for generic Abiraterone Acetate (NDC: 51672-4001) is projected to remain stable to moderately declining, ranging from $150 to $600 per month in the medium term, influenced by ongoing competition and payer policies.
- Future market positioning will depend on its utility within evolving treatment guidelines and its cost-effectiveness relative to emerging therapies.
Frequently Asked Questions
What is the typical dosage for Abiraterone Acetate (NDC: 51672-4001)?
The standard dosage for Abiraterone Acetate is 1000 mg orally once daily, taken on an empty stomach. This is typically administered in combination with prednisone or methylprednisolone.
How does Abiraterone Acetate compare to Enzalutamide for prostate cancer treatment?
Both Abiraterone Acetate and Enzalutamide are effective treatments for castration-resistant prostate cancer. Abiraterone Acetate inhibits androgen synthesis, while Enzalutamide is a more direct androgen receptor inhibitor. Clinical trial data suggests comparable efficacy in certain settings, but differences exist in their optimal sequencing and side effect profiles, leading to varied guideline recommendations.
What are the main side effects associated with Abiraterone Acetate?
Common side effects include fatigue, joint pain, nausea, diarrhea, hot flashes, and high blood pressure. More serious side effects can include liver toxicity, fluid retention, and cardiovascular events, particularly when combined with corticosteroids.
Can Abiraterone Acetate be used in earlier stages of prostate cancer beyond castration-resistant disease?
Yes, Abiraterone Acetate is approved for the treatment of newly diagnosed metastatic high-risk castration-resistant prostate cancer, either alone or in combination with prednisone, as well as for metastatic castration-resistant prostate cancer following docetaxel treatment.
What is the impact of payer coverage decisions on the availability of generic Abiraterone Acetate?
Payer coverage decisions significantly influence the accessibility and utilization of generic Abiraterone Acetate. Formulary placement, prior authorization requirements, and step-therapy protocols can dictate which patients have access to the drug and under what conditions, thereby affecting overall market demand and net pricing.
Sources
[1] Grand View Research. (2023). Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By Region, And Segment Forecasts, 2023 - 2030. [2] American Cancer Society. (2023). Cancer Facts & Figures 2023. [3] de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North S., Shore, N., ... & Griffin, G. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), 1995-2005. [4] Ryan, C. J., Smith, M. R., de Bono, J. S., Gill, W. S., Fandi, A., Song, W., ... & Scher, H. I. (2015). Abiraterone in metastatic castration-naive prostate cancer. New England Journal of Medicine, 372(10), 920-928. [5] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs/developmentapprovalprocess/drugapprovals/
More… ↓
